Ivacaftor / tezacaftor / elexacaftor (new indication: cystic fibrosis; in combination with ivacaftor; patients aged ≥ 6 - ≤ 11 years (heterozygous for F508del and MF mutation))

Subject:

• Active Substance: Ivacaftor / texacaftor / elexacaftor
• Name: Kaftrio^®
• Therapeutic area: Cystic fibrosis
• Pharmaceutical company: Vertex Pharmaceuticals (Germany) GmbH

Time table:

• Start: 15.02.2022
• Final decision by G-BA: 04.08.2022

Final decision:

• Indication for a considerable additional benefit